National Center for Advancing Translational Sciences Grants (Assistance Listing 93.350)

National Institutes of Health · Amount varies

This NIH STTR program (R41/R42) funds U.S. small businesses that partner with a nonprofit research institution to move scientific innovations toward commercialization. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · Amount varies

This NIH SBIR Phase IIB award is restricted to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award; it bridges the gap between Phase II and commercialization for later-stage R&D. Only one such award is allowed per project, and applications must be submitted within the first six due dates after the Phase II budget period ends, so it is narrow and limited to existing grantees. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH SBIR/STTR Commercialization Readiness Pilot (CRP) is restricted to U.S. small business concerns (as defined by the SBA) and helps move NIH-funded SBIR/STTR projects from late-stage development toward commercialization. It supports later-stage R&D and technical assistance such as replication studies, IND/IDE-enabling work, clinical studies, manufacturing scale-up, and regulatory support, and a significant portion may be subcontracted. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH/CDC/FDA SBIR program (R43/R44) funds U.S. small businesses developing scientific innovations toward commercial products through feasibility and R&D studies. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · Amount varies

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH R61/R33 funds milestone-driven development of clinical trials to treat co-occurring health conditions in people with Down syndrome — up to two years of planning followed by up to three years of trial support. Clinical trials are required.

National Institutes of Health · Up to $500K

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH R01 funds groundbreaking, high-impact Down syndrome research across any relevant topic, with no preliminary data required. Awards up to about $500,000.

National Institutes of Health · Amount varies

This NIH opportunity provides administrative supplements only to organizations that already hold an active, eligible NIH grant or cooperative agreement, to cover unforeseen increased costs within the scope of the existing project. New applicants without a current NIH award cannot use it. Funding is not guaranteed, and applicants must discuss requests with the awarding Institute's staff before submitting; foreign organizations may apply only consistent with the existing parent award.

National Institutes of Health · Amount varies

Open to U.S. universities, research institutions, nonprofits, and certain government/tribal organizations; foreign organizations are not eligible. This NIH R21 funds projects that improve clinical-trial readiness for rare diseases — developing biomarkers and outcome measures, or characterizing a disease's course to enable future trials. Award size follows standard R21 limits.

National Institutes of Health · Amount varies

Open to U.S. universities, research institutions, nonprofits, and certain government and tribal organizations; foreign organizations are not eligible. This NIH R21 funds exploratory, early-stage projects developing methods or agents to target 'undruggable' molecules in serious diseases. Award size isn't specified and follows standard NIH R21 limits; best suited to researchers pursuing high-risk, innovative therapeutics.

National Institutes of Health · Amount varies

This NIH (NCATS, T32) program funds eligible institutions to provide predoctoral research training in clinical and translational science for students pursuing a PhD or equivalent research degree. This is a limited competition; foreign institutions and non-U.S. components of U.S. organizations are not eligible to apply. It is intended for U.S. degree-granting research institutions, not individuals or general nonprofits. Award amounts are not specified, and the limited-competition framing suggests eligibility may be restricted to specific existing programs.

National Institutes of Health · Amount varies

This NIH (NCATS, T32) program funds eligible institutions to provide postdoctoral research training in clinical and translational science for individuals holding doctoral degrees across many health disciplines. This is a limited competition; foreign institutions and non-U.S. components of U.S. organizations are not eligible to apply. It is intended for U.S. research institutions, not individuals or general nonprofits. Award amounts are not specified, and the limited-competition framing suggests eligibility may be restricted to specific existing programs.

National Institutes of Health · Amount varies

The NIH parent Research Project Grant (R01, clinical trial not allowed) supports investigator-initiated research projects aligned with participating NIH institutes' missions, excluding clinical trials. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a core NIH research mechanism aimed at research institutions.

National Institutes of Health · Up to $650K

This NIH limited-competition award (UG3/UH3) funds collaborative innovation projects within the CTSA Program consortium to accelerate translational research. Eligibility is restricted per the funding notice, and foreign organizations and their U.S. components are not eligible, so this is aimed at institutions already in or aligned with the CTSA consortium rather than the general public. Awards run up to roughly $650,000. Review the notice's eligibility section closely, as access is limited.

National Institutes of Health · Up to $50K

This NIH R03 grant (up to $50,000) is a limited competition open only to current NCATS CTSA Program KL2 scholars and re-entry supplement recipients completing their transition to independent translational science careers. It's not open to researchers outside that specific CTSA cohort. The deadline is October 19, 2026.

National Institutes of Health · Amount varies

This NIH (NCATS, K12) program funds institutions to run mentored career development programs preparing later-stage postdoctoral fellows and junior faculty for independent clinical and translational research careers. This is a limited competition, and foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed; it is intended for eligible U.S. research institutions, not individuals or general nonprofits. Award amounts are not specified. The limited-competition framing suggests participation may be restricted to specific existing programs, so confirm eligibility in the full announcement.

National Institutes of Health · Amount varies

This NIH RC2 opportunity is a limited competition open only to institutions already holding a UM1 Clinical and Translational Science Award (CTSA) Hub grant, funding development of specialized research platforms and capabilities to address gaps in clinical and translational science. It is not open to applicants outside the existing CTSA Hub network. The deadline is September 28, 2026.

National Institutes of Health · Amount varies

This is a limited-competition NIH/NCATS research education (R25) grant supporting education programs within the Clinical and Translational Science Award (CTSA) program. Because it is a limited competition, eligibility is restricted to specific invited institutions rather than open to all applicants; foreign organizations are not eligible. No award amount is listed, and the eligibility text is narrow and does not fully specify which organizations may apply.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds preclinical efficacy studies in established rare-disease models to demonstrate that a candidate therapeutic warrants further development, including supporting pharmacokinetic and pharmacodynamic studies. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. It is intended for research teams advancing therapeutic candidates, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Up to $100K

This NIH (R03) opportunity funds pilot projects generating preliminary data on a defined list of understudied proteins associated with rare diseases. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $100,000.

National Institutes of Health · Amount varies

This NIH (R13) program supports conferences and scientific meetings relevant to public health and the missions of participating NIH institutes. Eligible applicants are U.S. research and education organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Note that R13 conference support typically requires advance permission from the funding institute before applying. It is aimed at organizations hosting scientific conferences, not individuals. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (NCATS, UM1) program funds Clinical and Translational Science Award (CTSA) hubs that join a national consortium to accelerate translational research, training, and rapid public health response. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible, though some foreign components are allowed. It is aimed at major academic medical and research institutions capable of operating a CTSA hub, not individuals or general nonprofits. Award amounts are not specified but such hubs are typically large, multi-year awards.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific NIH grants and need to transfer an award due to a change in organizational status (successor-in-interest). It is an administrative prior-approval request, not a new funding opportunity, and approval of the transfer is not guaranteed. Only current NIH grantee organizations should use it; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific types of NIH grants and need to transfer an existing award to a new recipient institution (a change of recipient organization). It is an administrative prior-approval request, not a new funding opportunity, and there is no guarantee a transfer will be approved. Only current NIH grantee organizations should apply; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

NIH mechanism allowing existing award recipients to apply for revision (supplemental) funding to expand a current NIH grant or cooperative agreement, only in response to a specific Notice of Special Interest. Restricted to organizations that already hold an active NIH single-project award. No award amount is specified. Because applicants must already be NIH grantees and respond to a matching NOSI, eligibility is narrow and not open to new applicants.